R&D News | pharmaphorum

News

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.

News

A PCR diagnostic developed by Roche for the Bundibugyo form of Ebola is being offered to health systems at the front lines of the current outbreak.

News

An AI-powered universal vaccine tech developed by UK biotech DIOSynVax has shown preliminary efficacy in a world-first human trial.

News

Parabilis has set the terms of its IPO, seeking to raise a hefty $475m for phase 3 trials of its lead drug for desmoid tumours.